The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 25, 2025
Filed:
Dec. 11, 2020
Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells
Regents of the University of Minnesota, Minneapolis, MN (US);
The University of North Carolina AT Chapel Hill, Chapel Hill, NC (US);
Albert-ludwig Universitat Freiburg, Freiburg, DE;
St. Jude Children's Research Hospital, Inc., Memphis, TN (US);
Bruce R. Blazar, Golden Valley, MN (US);
Brent Koehn, Elk River, MN (US);
Peter J. Murray, Memphis, TN (US);
Jenny P. Y. Ting, Chapel Hill, NC (US);
Robert Zeiser, Freiburg, DE;
Jeff S. Miller, Little Canada, MN (US);
Regents of the University of Minnesota, Minneapolis, MN (US);
The University of North Carolina at Chapel Hill, Chapel Hill, NC (US);
Albert-Ludwigs-Universität Freiburg, Freiburg, DE;
St. Jude Children's Research Hospital, Inc., Memphis, TN (US);
Abstract
In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.